This website would like to use analytics cookies. These send information about how our site is used to a service called Google Analytics. We use this information to improve our site.
Research is about finding out new knowledge that could lead to changes in treatments, policies or care. There are many different types of research from studies in a scientific laboratory to those that observe and examine people with different conditions or develop new treatments.
Research might be concerned with preventing disease and promoting good health or finding out people’s experience of different services and support in the community.
If you are eligible to participate in a research study then you will be asked by a clinician for your permission and its entirely up to you whether you take part.
As a research-focused practice, our commitment to supporting research projects is paramount in advancing medical knowledge and improving patient outcomes.
Your active participation ensures that our Practice remains at the forefront of innovation, contributing to a healthier future for all.
Over 40? Want to keep your brain sharp? You can join the PROTECT Research
This study investigates if a new medication reduces the risk of cardiovascular events, (such as heart attacks and strokes), in patients with CKD, inflammation, and cardiovascular disease. Anyone aged 18 or over is eligible if they have had a stroke, heart attack, or have insufficient blood flow in their legs, or have CKD which does not require dialysis or a transplant.
This study will involve regular clinic visits and phone calls for up to 4 years.
We are currently recruiting for the ZEUS trial. If you are eligible, you will receive a text from us, asking if you are interested in taking part.
What is the ZEUS Trial?
ZEUS is a global clinical study investigating if a new medication reduces the risk of having cardiovascular events, (such as a heart attacks and strokes), in people with Cardiovascular Disease, Chronic Kidney Disease, and inflammation. The trial is being run by Novo Nordisk.
Who can participate?
You will eligible to participate in this study if you meet all of the below: • Aged 18 or over • Have had a stroke or heart attack, or have insufficient blood flow in your legs • Have kidney disease which does not require dialysis or a transplant • Are able to attend regular clinic visits and receive phone calls over a period of up to 4 years.
What will be required if you participate?
You will go through a screening process to ensure you meet the criteria. If you do, the study Doctor will explain exactly what is expected of participants so you can make an informed decision. Your consent to participate, should you decide to join the trial will be taken and recorded. You will then receive the new medication, or a placebo, (a “dummy” which contains no medication which is given for comparison), once a month. You will then attend regular clinic visits with a study Doctor for up to 4 years, as well as receiving support, health, and lifestyle advice from the study staff.
How can I enrol?
If you would like to participate, please sign-up via the link in the text message you have received from us.
RESTORE
This study looks at Insomnia and whether a two-week trial of a medication is effective for severe insomnia. Patients aged between 18 and 75, with clinically significant impairment from severe insomnia, and have tried other sleep therapies that have failed are eligible.
This is all completed remotely via online surveys and video/ telephone calls for 7-8 weeks.
COAT – Cellulitis Optimal Antibiotic Treatment
The aim of this study is to assess the effectiveness and safety of a 5-day treatment of antibiotics compared to the standard 7-day treatment of patients who present with lower limb cellulitis, and to evaluate the cost consequences of a shorter course from an NHS and personal perspective.
Anyone over the age of 18 who is seen in the surgery with unilateral cellulitis of the leg is eligible to participate. Enrolled patients will be randomly allocated to either usual care, (7-day antibiotic treatment), or the 5-day antibiotic treatment trial.
All patients will be prescribed a 5-day course of Flucloxacillin and then will be posted two additional tablets, (either placebo or antibiotic), depending on which study arm they have been allocated to.
Virology Swabbing
If you attend the surgery with a cough or cold, you may be asked to carry out a Virology Swab of your throat and nose. The swab is then sent for testing to support national monitoring of flu, COVID-19 and other respiratory illnesses.
This programme measures the effectiveness of the Flu and COVID injections, and to monitor the spread of respiratory conditions in different regions throughout the year.
You will be advised of the result of the swab, and results will be used anonymously to provide WHO (World Health Organisation) with information to help them decide on the flu vaccine for the next winter and viruses in the local area they may need to develop vaccinations for in the future.
Serology Blood Test
If you attend for a blood test, you will be asked if you are happy for an extra vial of blood to be taken as part of the Serology project. These samples provide information about background levels of population immunity. Blood samples are tested with a number of assays to look at levels of exposure to COVID-19 infection and responses to vaccination.
Samples may also be used for testing antibody levels for other communicable diseases circulating in the community for the effectiveness of associated vaccines. No results are given to patients or their GP, and again the results remain anonymous.
OPTIMISE2 – Optimising Treatment for Mild Hypertension in Older People at Risk of Adverse Events
The aim of this study is to assess the longer-term effects of stopping blood pressure lowering medications in people aged 75 and over, who are taking two or more hypertensive medications and are at a higher risk of drug-related side effects but have a blood pressured in the normal range.
Participating patients will be randomised as to whether to continue with their normal treatment or have their hypertensive medications removed and will be actively followed-up for one year, examining whether deprescribing is safe in this patient group by measuring how many people are admitted to hospital the year after having blood pressure lowering drugs, compared to those who continued with them.
EMIS Recruit
You may receive a text from EMIS Recruit about clinical research. Which we support.
You have received this text as you have been highlighted as someone that could be eligible to help out with medical research.
You can either accept or decline this offer by following the advice in the text and links provided.
